KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Account Payables (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Change in Account Payables data on record, last reported at $11.4 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 211.76% year-over-year to $11.4 million; the TTM value through Dec 2025 reached -$8.4 million, up 74.55%, while the annual FY2025 figure was -$8.4 million, 74.55% up from the prior year.
  • Change in Account Payables reached $11.4 million in Q4 2025 per EBS's latest filing, up from -$4.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $31.0 million in Q1 2023 and bottomed at -$23.0 million in Q3 2024.
  • Average Change in Account Payables over 5 years is -$2.3 million, with a median of -$4.8 million recorded in 2021.
  • Peak YoY movement for Change in Account Payables: plummeted 1200.0% in 2021, then skyrocketed 585.71% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$5.1 million in 2021, then increased by 1.96% to -$5.0 million in 2022, then tumbled by 42.0% to -$7.1 million in 2023, then plummeted by 43.66% to -$10.2 million in 2024, then soared by 211.76% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $11.4 million in Q4 2025, -$4.0 million in Q3 2025, and -$10.4 million in Q2 2025.